Skip to main content
SpringerLink
Log in

Treatment Options for Testosterone Replacement Therapy

  • Chapter
  • First Online:
Androgen Deficiency and Testosterone Replacement

Part of the book series: Current Clinical Urology ((CCU))

  • 1106 Accesses

Abstract

Testosterone is the fastest growing medication in the USA today. There are many reasons for the rapid growth of the testosterone replacement therapy (TRT) market. We have an aging population with the number of US men 65 and older increasing two to three times faster than the number of men younger than 65. Furthermore, recent data demonstrate an increased association between poor general health, possibly mortality, and low serum testosterone levels. There is now less concern for the development of prostate cancer after TRT, making it a more attractive treatment option. Finally, new drugs entering the TRT market with increased promotion, marketing, and direct-to-consumer advertising are also driving market growth. Today, roughly 40 % of men over the age of 45 years old suffer from androgen deficiency and less than 10 % of these men are being treated. With such a large demand for treatment, clinicians should be aware of the different treatment options available.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Miller NL, Fulmer BR. Injection, ligation and transplantation: the search for the glandular fountain of youth. J Urol. 2007;177:2000–5.

    Article  PubMed  Google Scholar 

  2. Morales A, Tenover JL. Androgen deficiency in the aging male: when, who, and how to investigate and treat. Urol Clin North Am. 2002;29:975–82.

    Article  PubMed  Google Scholar 

  3. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60:762–9.

    Article  PubMed  CAS  Google Scholar 

  4. Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007;92:4241–7.

    Article  PubMed  CAS  Google Scholar 

  5. Wu FC, Tajar A, Pye SR, et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab. 2008;93:2737–45.

    Article  PubMed  CAS  Google Scholar 

  6. Kiratli BJ, Srinivas S, Perkash I, Terris MK. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology. 2001;57:127–32.

    Article  PubMed  CAS  Google Scholar 

  7. Stoch SA, Parker RA, Chen L, et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab. 2001;86:2787–91.

    Article  PubMed  CAS  Google Scholar 

  8. Bhasin S, Storer TW, Berman N, et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab. 1997;82:407–13.

    Article  PubMed  CAS  Google Scholar 

  9. Murray MP, Gardner GM, Mollinger LA, Sepic SB. Strength of isometric and isokinetic contractions: knee muscles of men aged 20 to 86. Phys Ther. 1980;60:412–9.

    PubMed  CAS  Google Scholar 

  10. Moffat SD, Zonderman AB, Metter EJ, Blackman MR, Harman SM, Resnick SM. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metab. 2002;87:5001–7.

    Article  PubMed  CAS  Google Scholar 

  11. Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab. 1996;81:4358–65.

    Article  PubMed  CAS  Google Scholar 

  12. Davidson JM, Chen JJ, Crapo L, Gray GD, Greenleaf WJ, Catania JA. Hormonal changes and sexual function in aging men. J Clin Endocrinol Metab. 1983;57:71–7.

    Article  PubMed  CAS  Google Scholar 

  13. van Roijen JH, Ooms MP, Weber RF, Brinkmann AO, Grootegoed JA, Vreeburg JT. Comparison of the response of rat testis and accessory sex organs to treatment with testosterone and the synthetic androgen methyltrienolone (R1881). J Androl. 1997;18:51–61.

    PubMed  Google Scholar 

  14. Bremner WJ, Vitiello MV, Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab. 1983;56:1278–81.

    Article  PubMed  CAS  Google Scholar 

  15. Braunstein GD. Testes. In: Greenspan FS, Strewler GJ, editors. Basic & Clinical Endocrinology. 6th ed, Chapter 12. Stamford, CT: Appleton & Lange; 1997. p. 422–52.

    Google Scholar 

  16. Petak SM, Nankin HR, Spark RF, Swerdloff RS, Rodriguez-Rigau LJ. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients—2002 update. Endocr Pract. 2002;8:440–56.

    PubMed  Google Scholar 

  17. Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab. 1999;84:3469–78.

    Article  PubMed  CAS  Google Scholar 

  18. Edelstein D, Dobs A, Basaria S. Emerging drugs for hypogonadism. Expert Opin Emerg Drugs. 2006;11:685–707.

    Article  PubMed  CAS  Google Scholar 

  19. Sih R, Morley JE, Kaiser FE, Perry 3rd HM, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab. 1997;82:1661–7.

    Article  PubMed  CAS  Google Scholar 

  20. Behre HM, Abshagen K, Oettel M, Hubler D, Nieschlag E. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur J Endocrinol. 1999;140:414–9.

    Article  PubMed  CAS  Google Scholar 

  21. Cummings DE, Kumar N, Bardin CW, Sundaram K, Bremner WJ. Prostate-sparing effects in primates of the potent androgen 7alpha-methyl-19-nortestosterone: a potential alternative to testosterone for androgen replacement and male contraception. J Clin Endocrinol Metab. 1998;83:4212–9.

    Article  PubMed  CAS  Google Scholar 

  22. Grober ED, Khera M, Soni SD, Espinoza MG, Lipshultz LI. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men. Int J Impot Res. 2008;20:213–7.

    Article  PubMed  CAS  Google Scholar 

  23. Marbury T, Hamill E, Bachand R, Sebree T, Smith T. Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim, compared to AndroGel. Biopharm Drug Dispos. 2003;24:115–20.

    Article  PubMed  CAS  Google Scholar 

  24. Kim S, Snipes W, Hodgen GD, Anderson F. Pharmacokinetics of a single dose of buccal testosterone. Contraception. 1995;52:313–6.

    Article  PubMed  CAS  Google Scholar 

  25. Gooren LJ. A ten-year safety study of the oral androgen testosterone undecanoate. J Androl. 1994;15:212–5.

    PubMed  CAS  Google Scholar 

  26. Cavender RK, Fairall M. Subcutaneous testosterone pellet implant (Testopel) therapy for men with testosterone deficiency syndrome: a single-site retrospective safety analysis. J Sex Med. 2009;6:3177–92.

    Article  PubMed  CAS  Google Scholar 

  27. McCullough AR, Khera M, Goldstein I, Hellstrom WJ, Morgentaler A, Levine LA. A multi-institutional observational study of testosterone levels after testosterone pellet (testopel(R)) insertion. J Sex Med. 2012;9:594–601.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Scott Department of Urology, Baylor College of Medicine, 6620 Main #1325, Houston, TX, 77030, USA

    Mohit Khera MD, MBA, MPH

Authors
  1. Mohit Khera MD, MBA, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohit Khera MD, MBA, MPH .

Editor information

Editors and Affiliations

  1. , Department of Urology, Tulane University Medical Center, 1430 Tulane Ave. SL-42, New Orleans, 70112, Louisiana, USA

    Wayne J.G. Hellstrom

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Khera, M. (2013). Treatment Options for Testosterone Replacement Therapy. In: Hellstrom, W. (eds) Androgen Deficiency and Testosterone Replacement. Current Clinical Urology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-179-0_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-179-0_10

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-178-3

  • Online ISBN: 978-1-62703-179-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation